Proinflammatory cytokines are suspected to play a role in the pathogenesis of multiple myeloma (MM). Therefore, it is possible that inborn genetic variations leading to a modified expression of these cytokines will influence the outcome for these patients. We investigated 348 MM patients undergoing high-dose melphalan treatment followed by Auto-SCT and examined the influence of single nucleotide polymorphisms (SNPs) in genes involved in the inflammatory response. We found that the polymorphism IL-1b T-31C significantly influenced overall survival (OS; P ¼ 0.02) and that carriers of the variant C-allele had a significantly longer survival than homozygous wild-type allele TT-carriers (relative risk 0.6 (95% CI ¼ 0.5-0.9); P ¼ 0.008). The polymorphisms IL-6 G-174C, IL-10 C592A, PPARc2 Pro 12 Ala, COX-2 A-1195G, COX-2 T8473C and NFKB1 ins/del did not influence the OS in this group of patients. Furthermore, homozygous carriers of the variant allele of IL-1b T-31C were at 1.37-fold (CI ¼ 1.05-1.80) increased risk of MM as compared with population-based controls (P ¼ 0.02). Our results indicate that IL-1b is involved in the pathogenesis of MM.
Introduction
The interaction between the myeloma cell and the BM microenvironment is central to the growth and survival of myeloma cells. The myeloma cell adheres to the BM microenvironment, and thereby stimulates angiogenesis and enhances the stimulation of cytokines such as IL-1b, IL-6 and IL-10. The proinflammatory cytokines released from the BM microenvironment activate the NF-kB (nuclear factor-kB) through the classical pathway in both the malignant myeloma cells and the innate immune system. This activation leads to further growth, adhesion and survival of myeloma cells and production of inflammatory mediators, such as IL-1b, IL-6 and cyclooxygenase 2 (COX-2). 1, 2 Another nuclear activation factor involved in the inflammatory response has been found in B-cell lymphomas and multiple myeloma (MM) cells. 3 The nuclear receptor, peroxisome proliferator-activated receptor-g (PPARg), is an important transcription factor and member of the nuclear hormone receptor superfamily. PPARg regulates the expression of COX-2, and prostaglandin 15d-PGJ 2 is a natural ligand for the PPARg that induces apoptosis in myeloma cell lines. 3 During the last decade, new treatments with immunomodulatory drugs and proteosome inhibitors have been introduced and have led to improved survival of the patients. These drugs induce apoptosis of myeloma cells, interrupt the interaction between myeloma cells and stromal cells in the BM, inhibit angiogenesis and inhibit the secretion of IL-1b and IL-6. The treatment effects of the new drugs support the importance of these key regulators of the immune response in the pathogenesis of MM. Inborn genetic variation in these genes may therefore be important for the risk, prognosis and treatment outcome of MM.
Proinflammatory cytokines, COX-2, NF-kB and PPARg are important for the regulation of inflammatory response as well as cancer cell growth. Several studies have shown a link between polymorphisms in IL-1b, IL-6, IL-10, COX-2, NF-kB and PPARg and cancer risk. [4] [5] [6] [7] [8] They may also be central to the pathogenesis of MM. New treatment strategies directed against these targets are being developed, and inborn variations in these genes may therefore become essential for the effect of such targeted therapy. In this study, we address the importance of the polymorphisms IL-1b T-31C, IL-6 G-174C, IL-10 C-592A, PPARg2 Pro 12 Ala, COX-2 A-1195G, COX-2 T8473C and NF-KB1-94ins/delATTG, which are known to affect the transcription levels of the genes and are also known to be important for cancer cell growth, inflammatory response and cancer risk, and the response to high-dose melphalan treatment.
Materials and methods
Patients, clinical data, response criteria, eligibility criteria and treatment Patients, clinical data, response criteria and eligibility criteria have been described in detail earlier. 9 Briefly, patients diagnosed with MM and treated with high-dose melphalan and auto-SCT from August 1994 to August 2004 were recruited from four participating centers in Denmark. A total of 348 patients were included in the study. Of these, 185 patients were included in the high-dose treatment protocols including Auto-SCT administrated by the Nordic Myeloma Study Group (nos. 5/94, 7/98 and 11/00), [10] [11] [12] whereas the remaining 163 patients were treated with similar regimens, but not registered in these protocols. Staging was performed according to Durie and Salmon. Time to treatment failure (TTF) and overall survival (OS) were calculated from the date of transplantation to the date of progression or death. Treatment-related mortality was 3%. Two patients died from malignancies other than MM, and two patients died because of other causes. The occurrence of other malignancies and death without progression was regarded as events not related to progression. These patients were included in the analysis of OS, but they were excluded at the time of death in the analysis of TTF. Time to treatment failure in 68 patients, including those who died during the transplantation procedure, was followed for less than 2 years. Induction therapy was three series VAD (vincristine, doxorubicin and dexamethasone) or 2-3 series of CY 1 g/m 2 once daily i.v. on day 1 combined with dexamethasone 40 mg daily p.o. on days 1-4 and days 9-11 (total dose 320 mg for each series). Peripheral blood stem cells were harvested at regeneration after CY priming, and the patients thereafter underwent high-dose chemotherapy with melphalan (200 mg/m 2 ) followed by Auto-SCT and maintenance therapy with interferon. A random sample of 800 individuals from the Danish Diet, Cancer and Health cohort was used for comparing the allele frequencies of the examined MM patients with the corresponding frequencies observed earlier. 13 The study was approved by the Danish Ethical Committee (01-158/03).
Human tissue samples
Peripheral blood mononuclear cells (PBMCs) were purified from 292 leukapheresis products by buffy coat preparation. From 56 patients, 10 times 10 mm sections were collected from paraffin-embedded BM samples. Material was not available for 19 patients undergoing Auto-SCT, and therefore these patients were not included in the study.
DNA purification DNA for analysis was purified from PBMCs by the salting out method 14 or from paraffin-embedded tissue by phenol extraction as described. 15 Detection of single nucleotide polymorphism (SNPs) Genotypes were determined on an ABI 7500 using end point readings. Reactions of 5 ml contained approximately 50 ng DNA, 2.5 ml mastermix (Applied Biosystems, Birkerd, Denmark), 100 nM of each probe and 900 nM primers. Controls were included in each run, and repeated 10% subset yielded 100% identical genotypes. Moreover, for 10 persons, DNA from both BM and leukapheresis products was genotyped with identical results.
12 Ala (rs1801282), COX-2 C8473T (rs5275) and COX-2 A-1195G (rs689466) were genotyped as described earlier. 13 For NF-kB ins/del (rs28362491), the primer sequences were F: 5 Fisher's exact test was used for comparing categorical variables and the Mann-Whitney test was used for comparing continuous and categorical variables. The Kaplan-Meier method and the log-rank test were used to compare TTF and OS between groups. The Cox proportional hazards model, log-likelihood statistics, was applied for univariate analyses of covariates and for multivariate analysis. Significant variables with a P-value o0.05 by univariate analysis were included in the multivariate Cox analyses to identify variables of independent significance. Analysis of risk was performed as a case-control study. The frequencies of the different genotypes were compared in the myeloma patients and in a control group. For significance testing, Fisher's exact test was used. The comparison group was described in a recent publication by Vogel et al.
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Results
SNP
Genotypes of IL-1b T-31C, IL-6 G-174C, IL-10 C592A, PPARg2 Pro 12 Ala, COX-2 A-1195G, COX-2 T8473C and NF-KB1-94ins/del were determined. There was no difference in the allele frequencies among patients from different participating centers. The allele frequencies of the examined MM patients were compared with the corresponding frequencies observed earlier in a random control sample. No difference was found in the distribution of the genotypes IL-6 G-174C, IL-10 C592A, PPARg2 Pro 12 Ala, COX-2 A-1195G and COX-2 T8473C when compared with the comparison group. Heterozygous carriers of the Callele of IL-1b T-31C were at 1.15-fold higher risk of MM (CI ¼ 0.94-1.41), and homozygous carriers were at 1.37-fold increased risk of MM (CI ¼ 1.05-1.80) (P ¼ 0.02) than homozygous carriers of the wild-type allele when compared with the random sample of 753 persons from the Diet, Cancer and Health cohort. The effect of the genotypes on TTF and OS was tested in univariate analysis, and the results are presented in Table 1 . TTF data adjusted for b2-microglobulin and OS data adjusted for all other survivalrelated factors (b2-microglobulin, creatinine and DurieSalmon stage) are shown in parentheses.
There was no difference in TTF for any of the polymorphisms studied. Carriers of the variant C-allele of IL-1b T-31C had a median OS of 80.1 months when compared with a median OS of 48.5 months for the homozygous carriers of the wild-type T-allele (P ¼ 0.008; Figure 1 and Table 1 ). The correlation was still statistically significant after adjustment for all other prognostic factors known to influence OS (b2-microglobulin, creatinine and Durie-Salmon stage). The correlation of polymorphism in IL-1b T-31C with OS was even more marked when analyzed after treatment failure. Analyzed from the time of progression, carriers of the variant C-allele of IL-1b T -31C had a median OS of 37.1 months when compared with a median OS of 16.2 months for the homozygous carriers of the wild-type T-allele (P ¼ 0.002). There was no correlation between the allele distribution of polymorphism IL-1b T-31C and treatment outcome either after induction treatment or after Auto-SCT (Table 2) . There was no effect on patient survival of the polymorphisms IL-6 G-174C, IL-10 C-592A, PPARg2 Pro 12 Ala, COX-2 A-1195G, COX-2 T8473C and NF-KB1-94ins/del. There was no interaction between sex and genotypes in relation to TTF and survival.
Combination analyses of SNPs
The proinflammatory cytokines studied are known stimulators of myeloma cell growth. The three polymorphisms IL-1b T-31C, IL-6 G-174C and IL-10 C592A were combined, and the effect on TTF and OS of these combinations were investigated in a univariate analysis (Table 3) .
There was no association between IL-1b T-31C, IL-6 G-174C and IL-10 C592A polymorphisms. No additive effect on survival was seen when the variant genotype of IL-1b was combined with the genotypes of IL-6 or IL-10. The variant alleles of the two COX-2 polymorphisms, COX-2 A-1195G and COX-2 T8473C, are not part of the same haplotype. 16 Consequently, we tested combinations of these polymorphisms, but no additional effects on TTF or OS were seen (Table 3) .
Multivariate analysis of prognostic markers
The IL-1b T-31C polymorphism was compared with known prognostic factors (b2-microglobulin, creatinine, albumin, sex, age and Durie-Salmon stage). No significant covariance was found (Table 4) .
The polymorphism IL-1b T-31C was examined in a multivariate analysis to see whether it had independent prognostic value. IL-1b T-31C was tested separately against the statistically significant parameters from the univariate analyses to calculate the adjusted hazard ratios and Pvalues. In one center, b2-microglobulin was not analyzed routinely. Therefore, only 240 patients were available in the multivariate analysis with IL-1b T-31C. The adjusted hazard ratios and P-values were similar to the unadjusted hazard ratios (Table 5) .
Using a wider range of the commonly used prognostic variables (age, sex, albumin, creatinine, b2-microglobulin and Durie-Salmon stage) and a backward stepwise method, the IL-1b T-31C polymorphism stayed in the model as a statistically significant prognostic factor (P ¼ 0.04) together with age (P ¼ 0.02), sex (P ¼ 0.04) and b2-microglobulin (P ¼ 0.0002).
Discussion
Immunological and inflammatory response genes are of particular interest in hematological malignancies because these genes both participate in the normal recruitment and differentiation of hematopoietic cells, the normal immune response and may be of importance in carcinogenesis. Several cytokines function as paracrine and autocrine growth factors and are expressed in both myeloma cells and in BM stromal cells. In contrast to myeloma cells, BM stromal cells are expected to have normal regulatory functions. The myeloma cells home in the BM, where the interaction with BM stromal cells may be crucial for further development, growth and resistance to chemotherapy. 17 In this study, we have addressed the question how inborn variations in genes involved in the immune and inflammatory responses influence the outcome of patients with MM treated with high-dose melphalan and Auto-SCT. Furthermore, we have analyzed whether any of the examined polymorphisms are associated with the risk for development of MM.
The polymorphism IL-1b T-31C influenced OS. We found that patients carrying the variant C-allele (CT þ CC, 59% of patients) had an increased OS of 80.1 months compared with 48.5 months for the homozygous carriers of the wild-type T-allele (TT, 41% of patients) (P ¼ 0.008). The effect on OS was more pronounced when examined after TTF. Furthermore, IL-1b T-31C was found to be a statistically significant prognostic marker for prolonged OS in a Cox multivariate analysis.
IL-1b has several functions in man and is induced by nearly all microbial and many inflammatory substances and cytokines. It is expressed mainly by BM stromal cells, but is also expressed by myeloma cells and, to a lesser extent, by plasma cells in patients with monoclonal gammopathy of undetermined significance (MGUS). [18] [19] [20] IL-1b is important for both regulation of inflammation and of host defense in man, and it stimulates the production of IL-6, an important growth factor for MM cells. A recent study has shown that IL-1b-induced stimulation of IL-6 The polymorphism IL-1b T-31C and multiple myeloma AJ Vangsted et al production in BM stromal cells is higher in stromal cells from patients with myeloma than in stromal cells from patients with MGUS. The effect on IL-6 production was inhibited by IL-1 antagonists. 20 This finding indicates that IL-1b is linked with the progression of MGUS to MM. We found that homozygous carriers of the variant C-allele of IL-1b T-31C were at increased risk of MM (relative risk of 1.37; CI ¼ 1.05-1.80) compared with random samples of healthy Danes aged 50-64 years. 16 The finding suggests that high IL-1b levels are associated with the increased risk of MM. However, as cases and comparison groups were not matched, the observation needs further examination in a proper case-control study of patients with MGUS and MM.
The association between IL-1b T-31C and both OS and risk of MM emphasizes the possible biological importance of IL-1b in the pathogenesis of MM. There are several functional SNPs in the promoter region of IL-1b. A Japanese study of helicobacter pylori-infected patients showed that homozygous carriers of the variant allele of the polymorphism IL-1b C-511T had higher IL-1b mucosa levels than did carriers of the wild-type C-allele and in patients with systemic inflammatory response syndrome, high IL-6 blood levels were found in carriers of T-allele. 21 Another recent study shows that the two polymorphisms IL-1b T-31C and C-511T are in complete linkage equilibrium and that the two variant alleles cosegregate completely. Thus, the variant allele with the two polymorphisms is always present in the same haplotype. The study showed that although the variant C-allele of T-31C has less transcriptional activity when analyzed separately, the haplotype encompassing both variant alleles in positions À31 and À511 has a higher transcriptional response to LPS and phorbol 12-myristate 13-acetate (PMA) stimulation in the human monocytic cell line than the haplotype encompassing the wild-type alleles. 22 This result is supported by a recent study on lung epithelial cells that found that the variant allele in position À31 had a lowered transcription level when analyzed separately. 23 We observed increased survival among patients with a higher inborn IL-1b transcription level and cytokine level. We found no difference in relation to polymorphism in the IL1b gene and TTF after high-dose therapy and in relation to the response to induction treatment or Auto-SCT (Table 2 ). This would mean that IL-1b levels do not influence the outcome of Auto-SCT, but probably influence other aspects of the disease or treatment strategy after Auto-SCT. One possibility is that the high IL-1b levels may delay the clonal expansion of myeloma cells surviving the highdose chemotherapy by representing a biological feature of a less aggressive disease. The immune system may be a part of this protection. IL-1b has been shown to be important for the development of human T-helper cells 24 and for the generation of mature IL-12-producing dendritic cells from circulating monocytes from MM patients. 25, 26 Another possibility is that IL-1b influences the treatment outcome of new immunomodulating drugs used after the recurrence of the disease.
There was no effect on TTF and patients' survival of the polymorphisms IL-6 G-174C, IL-10 C-592A, PPARg2 Pro 12 Ala, COX-2 A-1195G, COX-2 T8473C and NF-KB1-94 ins/del, and we found no correlation between the risk of MM and the polymorphisms IL-6 G-174C and IL-10 C592A. The results of IL-6 G-174C and IL-10 C592A are in accordance with other smaller studies of MM. 27, 28 Polymorphisms in PPARg2 Pro 12 Ala, COX-2 A-1195G and COX-2 T8473C have not been studied in relation to the risk of MM before. In our study, the polymorphisms COX-2 A-1195G, COX-2 T8473C and PPARg2 Pro 12 Ala were not associated with the risk of MM or outcome of disease. Therefore, the polymorphisms in these genes cannot explain the discrepancy in the results of the effect of COX inhibitors in relation to the risk of disease and outcome in patients with MM. 29 However, our observations do not exclude important functions of the inflammatory-related genes in the pathogenesis of MM.
Standard treatment for younger patients with MM is high-dose melphalan treatment and autologous stem cell support. This treatment improves the survival but will not cure the patients. 10 Treatment outcome for patients with MM depends on factors related to the aggressiveness of the tumor, the tumor burden at diagnosis, choice of treatment and inherited genetic variations that modify the response to treatment. We have shown earlier that the treatment outcome may be influenced by inherited variation in the individuals' capacity for DNA repair. 9 Polymorphisms in the DNA repair genes ERCC2, XRCC3 and CD3EAP significantly influenced the treatment outcome of patients with MM undergoing high-dose treatment. There is ample evidence to show that proinflammatory cytokines are involved in the risk of cancer, but less is known about their importance for treatment outcome and survival.
In this study, we found an increased frequency of the variant allele IL-1b T-31C in MM patients. The IL-1b T-31C polymorphism did not play any role in the outcome of treatment with high-dose melphalan and Auto-SCT, but carriers of the variant C-allele had a significantly longer survival than did homozygous wild-type allele TT carriers. The hazard ratios of progression for the variants were calculated with respect to having wild-type in IL-1b T-31C. The P-value is used for all combinations as a categorical variable.
